RxDoctor Payments DataLook up a doctor →

Rachel Hollywood

Family · Ocean, NJNPI 1124498415

Payments from drug & device makers

$12,084in general payments, 2019–2025

Across 672 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • AbbVie$2K
  • GSK$810
  • Pfizer$414
  • Regeneron Healthcare Solutions, Inc.$401
  • Amgen$398
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$11,88698%
  • Education$1982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,084 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$74,832
Medicare patients
159
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol31$40,874
OzempicSemaglutide20$38,305
MounjaroTirzepatide22$26,887
EliquisApixaban26$19,304
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$14,144
ZtlidoLidocaine13$13,805
Repatha SureclickEvolocumab13$9,752
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$9,666
AirsupraAlbuterol Sulfate/Budesonide12$5,537
SteglatroErtugliflozin Pidolate28$4,734
Paroxetine Hcl67$2,251
Celecoxib38$1,837
Levothyroxine Sodium182$1,799
Atorvastatin Calcium184$1,659
Oxybutynin Chloride ErOxybutynin Chloride41$1,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Airsupra$3,445$56,07758 claims
Novo NordiskOzempic$255$38,30520 claims
Lilly USA, LLCMounjaro$321$26,88722 claims
PfizerEliquis$414$19,30426 claims
GSKTrelegy Ellipta$810$14,14415 claims
Scilex Pharmaceuticals Inc.Ztlido$110$13,80513 claims
MerckSteglatro$264$4,73428 claims
AbbVieSynthroid$1,706$96816 claims
Almatica Pharma LLCSertraline Hcl$16$60084 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.

Other family in Ocean

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →